Centro Medico Sheba
Bookimed non aggiunge costi extra ai prezzi dei trattamenti di Immunoterapia. Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica al tuo arrivo nel paese.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali nei trattamenti di Immunoterapia e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di trattamento per Immunoterapia.
Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.
She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.
She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.
She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.
Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.
He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.
He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.
Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.
He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.
He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.
Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.
He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.
Sheba Medical Center and Tel Aviv Sourasky Medical Center lead Israel in immunotherapy. These institutions offer advanced CAR T-cell and TIL therapies. They maintain JCI accreditation and international partnerships. Specialist centers deliver targeted protocols for melanoma, sarcomas, and blood cancers within 10–11 days.
Bookimed Expert Insight: Sheba Medical Center uniquely combines massive scale with elite specialization. It serves 2 million patients yearly and holds 8 consecutive Newsweek Top-10 rankings. Data shows over 200 of its physicians are Forbes-rated. This concentration of expertise is rare. Patients often find that the most complex cases are referred here because the facility manages everything from cellular manufacturing to multidisciplinary tumor boards in one location.
Patient Consensus: Patients note that finding an oncologist who specializes in your exact cancer subtype is more important than the hospital's overall name. They also emphasize getting biomarker testing done early to ensure immunotherapy will actually work for their specific tumor.
Israel offers advanced immunotherapies including on-site CAR T-cell manufacturing and Tumor-Infiltrating Lymphocyte (TIL) therapy. Facilities like Sheba Medical Center culture cells domestically. This reduces processing times to 10–11 days. Proprietary pipelines also provide access to monoclonal antibodies and cancer vaccines through active clinical trials.
Bookimed Expert Insight: Israeli oncology centers demonstrate a unique integration of research and practice. Sheba Medical Center treats over 2 million patients annually. This massive volume allows their doctors, like Prof. Raanan Berger, to manage complex immunotherapy side effects effectively. Patients often choose Israel because academic hospitals can fast-track cell manufacturing in-house. This saves weeks compared to shipping cells to commercial labs in other countries.
Patient Consensus: Patients emphasize the importance of bringing detailed molecular testing and pathology records for eligibility. They note that Israeli centers offer faster access to new checkpoint inhibitors and active trials.
Immunotherapy side effects stem from an overactive immune system attacking healthy organs. This differs from chemotherapy, which directly poisons rapidly dividing cells. Immunotherapy causes inflammatory issues like colitis or pneumonitis. Chemotherapy typically triggers immediate hair loss, severe nausea, and dangerously low blood counts.
Bookimed Expert Insight: Israeli centers like Sheba Medical Center prioritize precision protocols like TIL and CAR-T immunotherapy. Our data shows these facilities leverage integrated research to manage the unique `delayed fatigue` seen in immunotherapy. While chemotherapy exhaustion is immediate, immunotherapy fatigue often signals thyroid or adrenal inflammation. High-volume centers often catch these subtle hormonal shifts earlier than general oncology wards.
Patient Consensus: Patients note they can often function normally at first with immunotherapy. They warn not to ignore mild symptoms like a persistent cough or itchy skin. These early signs often point to inflammatory side effects that require medical attention.
Israeli oncologists pivot to alternative strategies if immunotherapy drugs fail. Patients may transition to targeted therapy or chemotherapy based on tumor mutations. Experts also utilize combination regimens. These combine immunotherapy with radiation or other treatments to overcome primary or acquired resistance.
Bookimed Expert Insight: Israeli oncology centers like Sheba Medical Center often transition patients to revolutionary cellular therapies when standard drugs fail. Sheba offers TIL immunotherapy and CAR-T treatments that are unavailable in many countries. This capability is supported by over 200 Forbes-ranked doctors within a single facility. Choosing a center with integrated research departments allows for a faster pivot to these advanced protocols.
Patient Consensus: Patients emphasize the importance of requesting deep molecular profiling early to avoid wasting time on ineffective drugs. They stress that having a specific second-line plan ready by the eight-week mark is crucial for maintaining treatment momentum.
Immunotherapy in Israel is primarily administered via intravenous infusion, taking between 30 and 90 minutes. Centers like Sheba Medical Center also offer advanced cellular therapies. These include CAR-T and TIL therapies. Some medications are delivered as subcutaneous injections, taking under 5 minutes.
Bookimed Expert Insight: Israeli oncology centers like Sheba Medical Center are global leaders in TIL and CAR-T therapies. These are not standard infusions but specialized cellular treatments. While standard immunotherapy takes about an hour, cellular therapy requires intensive hospital coordination. Data shows Sheba treats over 2,000,000 patients annually and maintains JCI safety standards.
Patient Consensus: Patients note the first appointment often takes several hours for safety monitoring. They suggest bringing a charger and snacks since pre-treatment blood work adds extra waiting time.
International patients receive remote second opinions from Israeli oncology centers to verify immunotherapy eligibility before traveling. Leading facilities like Sheba Medical Center use telemedicine to review pathology and imaging files. Specialist consultations confirm if advanced protocols like CAR-T or TIL are viable options.
Bookimed Expert Insight: Israeli oncology centers often integrate remote reviews into their arrival workflow. At Sheba Medical Center, which treats nearly 2 million patients annually, telemedicine helps triage complex cases for specialized therapies. Data suggests consulting with a department director during the remote phase ensures your treatment plan is ready for immediate implementation upon arrival.
Patient Consensus: Patients note that organizing medical records beforehand is essential to avoid delays. They recommend requesting a written summary of the video call to share with local doctors for better care continuity.